Berlin, Germany

Olaf Panknin

This inventor holds 17 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 11 EPO patents, primarily in Magnetic Resonance Imaging. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Olaf Panknin. Retrieved from https://idiyas.com/inventor/olaf-panknin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 76.5

 

 

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 41(Granted Patents)


Company Filing History:


Years Active: 2018-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Furoindazole Derivatives
Gadolinium Chelate Compounds
High Relaxivity Gadolinium
Magnetic Resonance Imaging
Substituted Pyrrolopyridine-derivatives
MKNK1 Inhibitors
MKNK2 Inhibitors
Fused Imidazoles
Benzimidazol-2-amines
mIDH1 Inhibitors
Tumor Treatment
17 patents (USPTO):Explore Patents

Certainly! Here is the article about inventor Olaf Panknin:

Title: Olaf Panknin: A Trailblazer in Innovation

Introduction:

Olaf Panknin, a renowned inventor based in Berlin, DE, has captured the essence of relentless pursuit of innovation in the world of inventions. With an impressive portfolio of 15 patents under his belt, Panknin's commitment to creating a better future through groundbreaking technology places him as a standout figure in the industry.

Latest Patents:

Panknin's latest patents showcase his groundbreaking work in the field of medical imaging. One notable invention includes the development of high relaxivity gadolinium chelate compounds for use in magnetic resonance imaging. These novel compounds promise enhanced imaging capabilities, revolutionizing the way healthcare professionals diagnose and treat patients.

Career Highlights:

Throughout his illustrious career, Panknin has made significant contributions while working at Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. His innovative spirit and dedication to pushing the boundaries of technological advancements have earned him a reputable status within the industry.

Collaborations:

Panknin has collaborated with esteemed colleagues such as Katja Zimmermann and Roland Neuhaus, further enriching his innovative projects with diverse expertise and perspectives. Together, they have paved the way for cutting-edge developments that continue to shape the landscape of inventions.

Conclusion:

Olaf Panknin's unwavering passion for innovation and his ceaseless efforts to drive positive change through technology have set a new standard in the world of inventions. His work serves as an inspiration for the next generation of inventors, highlighting the transformative power of creativity and perseverance in creating a brighter future for all.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…